Recent studies have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic communication. While GCGR activators are commonly employed for treating type 2 T2DM, their potential effects on reward circuits, specifically influenced by dopamine pathways, ar